Orexigen discloses patents with data on Contrave effect on CV outcomesOrexigen disclosed in a regulatory filing that on March 3 the United States Patent and Trademark Office issued U.S. Patent No. 8,969,371 and made publicly available provisional patent applications to which the '371 Patent claims priority. The '371 Patent and the Provisional Patent Applications incorporate data from a pre-planned interim analysis of the large, randomized, placebo-controlled, cardiovascular, or CV, outcomes trial of Contrave, or the Light Study. The '371 Patent, which expires in 2034, is the first in the Light Study family of patent applications Orexigen has prosecuted and covers two subgroups of the larger Light Study patient population. The Provisional Patent Applications are part of the same family of patent applications that were first filed in December 2013. The '371 Patent and the Provisional Patent Applications contain claims related to a positive effect of Contrave on CV outcomes. The observed effects on CV outcomes were unexpected and appear to be unrelated to weight change, the company said. Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition "Importantly, the U.S. package insert for Contrave states that the effect of Contrave on CV morbidity and mortality has not been established," the company noted. For regulatory approval purposes, the Light Study included a pre-planned interim analysis designed to exclude a doubling of CV risk compared to placebo. This analysis was conducted based on 94 observed and adjudicated major adverse cardiovascular events, which was approximately 25% of the planned MACE for the Light Study. The 25% Interim Analysis was prospectively designed to enable an early and preliminary assessment of safety to support regulatory approval. A larger number of MACE are required to precisely determine the effect of Contrave on CV outcomes, Orexigen said.

Navistar sees Q2 adjusted EBITDA $100M-$150MSees Q2 manufacturing cash, cash equivalents and marketable securities between $700M-$800M. The company reiterated its forecast for retail deliveries of Class 6-8 trucks and buses in the United States and Canada to be in the range of 350,000 to 380,000 units for fiscal year 2015. It also announced that it remains on track to achieve its goal of an 8-10 percent adjusted EBITDA margin run rate exiting fiscal year 2015.

Ciena March weekly volatility elevated into Q1 and outlook Ciena March weekly call option implied volatility is at 76, April is at 49, July is at 40; compared to its 26-week average of 43 according to Track Data, suggesting larger near term price movement into the expected release of Q1 results before the open on March 5.

Ultragenyx adds Orexigen CEO to boardUltragenyx Pharmaceutical (RARE) announced the appointment of Michael Narachi to the company's board, effective February 20. Narachi, President and CEO and a director of Orexigen Therapeutics (OREX), will serve as an independent director to Ultragenyx.

Citigroup sees truck carrier stocks poised to outperformWith the U.S. economy growing quickly, the stocks of truck carriers are likely to outperform the S&P 500, Citigroup believes. WHAT'S NEW: Truck transportation prices and truck carrier stocks "respond most directly to economic growth," Citigroup analyst Christian Wetherbee wrote in a note to investors today. After carriers' truckload rates rose 4% last year, the rates should rise by a similar amount this year, Wetherbee predicted. Economic growth, along with the difficulties the carriers are experiencing with recruiting drivers, should be supportive of additional rate increases, the analyst stated. Wetherbee warned that the stocks of truck builders usually underperform during periods such as the current one, when a large amounts of U.S. class 8 trucks are being built. Consequently, truck carrier stocks present investors with an opportunity, while investors should be cautious on truck builders and parts suppliers, he wrote. Among truck carriers, Swift (SWFT) is particularly attractive, since it has underperformed its peers over the last year, Wetherbee stated. Additionally, the company's results appear likely to at least meet consensus estimates, the analyst predicted. He also kept a Buy rating on another truck carrier, Knight Transportation (KNX) and maintained a Buy rating on Cummins (CMI), which builds truck engines. The analyst kept a Hold rating on truck builder PACCAR (PCAR). OTHERS TO WATCH: Navistar (NAV) builds trucks and Celadon (CGI) is another truck carrier. PRICE ACTION: In early afternoon trading, Swift rose 1%, Knight Transportation gained 1.3%, Cummins added 0.7%, and PACCAR lost 0.5%.

Ebix up 9% after report of London market tender winShares of Ebix are up 9% after Insurance Insider reported the company won the tender for developing a platform that will allow electronic placement to be introduced in London market. Reference Link